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Background: In heart failure, the release of calcium becomes erratic leading to the generation of arrhythmias. Dysregulated
Zn2 homeostasis occurs in chronic heart failure.
Results: Zn2 can directly activate RyR2, removing the dependence of Ca2 for channel activation.
Conclusion: Zn2 shapes Ca2 dynamics by directly interacting with and modulating RyR2 function.
Significance: This highlights a new role for Zn2 in cardiac excitation-contraction coupling.
Aberrant Zn2 homeostasis is a hallmark of certain car-
diomyopathies associated with altered contractile force. In this
study, we addressedwhether Zn2modulates cardiac ryanodine
receptor gating and Ca2 dynamics in isolated cardiomyocytes.
We reveal that Zn2 is a high affinity regulator of RyR2 display-
ing three modes of operation. Picomolar free Zn2 concentra-
tions potentiate RyR2 responses, but channel activation is still
dependent on the presence of cytosolic Ca2. At concentrations
of free Zn2>1 nM, Zn2 is the main activating ligand, and the
dependence on Ca2 is removed. Zn2 is therefore a higher
affinity activator of RyR2 than Ca2. Millimolar levels of free
Zn2 were found to inhibit channel openings. In cardiomyo-
cytes, consistent with our single channel results, we show that
Zn2 modulates both the frequency and amplitude of Ca2
waves in a concentration-dependent manner and that physio-
logical levels of Zn2 elicit Ca2 release in the absence of acti-
vating levels of cytosolic Ca2. This highlights a new role for
intracellular Zn2 in shaping Ca2 dynamics in cardiomyocytes
through modulation of RyR2 gating.
In cardiac muscle, the intracellular signal that triggers
muscle contraction is thought to be a transient rise in intra-
cellular Ca2 that leads to the opening of Ca2 release chan-
nels called type 2 ryanodine receptors (RyR2)2 on the sarco-
plasmic reticulum (SR). The resulting release of Ca2 into
the cytosol causes movement of contractile myofibrils lead-
ing to cell contraction. Damaging changes in Ca2 homeo-
stasis are associated with heart failure, conduction abnormalities,
and contractile dysfunction. Abnormal RyR2 function is recog-
nized as an important component in the etiology of such disease
states (1–3).
Recently, there has been much interest in the role of Zn2 as
an intracellular signaling molecule (4–6). Like Ca2, intracel-
lular Zn2 is heavily buffered (7), and cellular Zn2 homeosta-
sis requires mechanisms that tightly control the uptake, stor-
age, and distribution of Zn2. This is achieved through the
coordinated actions of metallothionein proteins and Zn2
transporters (8–10).
In cardiomyocytes, the resting intracellular Zn2 concentra-
tion is reported to be at picomolar levels (100 pM) (11, 12).
During cardiac excitation-contraction coupling, intracellular
Zn2 concentrations are altered, and spatiotemporal fluctua-
tions in free Zn2 levels, including both Zn2 transients and
Zn2 sparks, are suggested to be remarkably similar to those
previously shown for Ca2 (13). Other groups suggest that
Zn2 can permeate through the L-type channel with a greater
affinity than Ca2 but with a much lower permeability leading
to a reduction in the inward current (14, 15). It has also been
suggested that the SR can function as an intracellular store for
Zn2 alongside Ca2 (6, 13).
Importantly aberrant Zn2 homeostasis has been shown to
be associated with cardiomyopathy including chronic heart
failure, andmyocardial damage as a result of dysregulated intra-
cellular Ca2 release, reduced cardiac contractility, and signif-
icantly prolonged rises of systolic Ca2 (16–19). The potential
role of Zn2 in shaping intracellular Ca2 release and regulat-
ing intracellular Ca2 dynamics in heart however, is poorly
characterized. Here we show that Zn2 is a potent regulator of
SR Ca2 release through modulation of RyR2 channel function
and that Zn2 plays a key role in shaping intracellular Ca2
dynamics important in cardiac excitation-contraction coupling.
Experimental Procedures
Reagents—Chemicals were AnalaR or the best equivalent
grade from BDH Chemicals (Poole, UK) or Sigma-Aldrich. All
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solutions were made in deionized water, and those for use in
bilayer experiments were filtered through a Millipore mem-
brane filter (0.45-m pore). 2,2-(Ethylenedioxy)dianiline-
N,N,N,N-tetraacetic acid (BAPTA) (Dorset, UK) and
N,N,N,N-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) were
fromSigma-Aldrich.
SR Vesicle Preparation and Planar Phospholipid Bilayer
Techniques—Sheep hearts were obtained from a local abattoir,
and heavy SRmembrane vesicles were prepared and fused with
planar phosphatidylethanolamine lipid bilayers, as described
previously (20). Briefly, heavy SR vesicles were prepared as fol-
lows. Homogenized ventricular cardiac tissue from sheep was
subjected to centrifugation at 6,500  g followed by ultracen-
trifugation of the supernatant at 100,000  g. The heavy SR
membrane fraction was obtained from loading mixed mem-
branes onto a discontinuous sucrose density gradient.Heavy SR
was collected, snap frozen in liquidN2, and stored at80 °C.As
reported previously, SR vesicles fused in a fixed orientation
such that the cis-chamber corresponded to the cytosolic face of
the channel and the trans-chamber to the SR lumen (21, 22).
The trans-chamber was held at ground and the cis-chamber at
potentials relative to ground. After fusion, the cis-chamber was
perfusedwith 250mMHEPES, 80mMTris, and 10M free Ca2
(pH 7.2). The trans-chamber was perfused with 250 mM glu-
tamic acid and 10 mM HEPES (pH to 7.2) with Ca(OH)2 (con-
centration of free Ca2 50 mM). The identity of RyR2 was
confirmed by the single-channel conductance, and the number
of channels gating in the bilayer was assessed by the application
of caffeine at the end of the experiment. Zn2 was added as
ZnCl2 to the cis-chamber at the required concentration froman
appropriate stock solution. 100mM stock solution of ZnCl2 was
prepared in 0.029 M HCl, and serial ZnCl2 dilutions were made
in a Tris/HEPES buffer which contained, 250 mM HEPES, 80
mM Tris, and 10 M free Ca2 (pH 7.2) to make appropriate
stock solutions. The concentration of each Zn2 stock was fur-
ther assessed using a pZn meter (Neurobiotex.com, Galveston,
TX) as previously described (23) to confirm the accuracy of our
serial dilutions. The lowest concentrationZn2 stockmadewas
10 nM. The addition of 100M ZnCl2 to our Tris/HEPES buffer
had no significant effect on the pH (pHwas 7.22 0.014 before
and 7.21  0.016 after the addition of 100 M ZnCl2; n  3).
Special care was taken when preparing Zn2 stock solutions.
All glassware was prewashed with 100 nM TPEN and then
rinsed carefully with MilliQ water passed through a Chelex
Resin (Bio-Rad). The use of colored pipette tips was also
avoided.
Experiments were carried out at room temperature (22 
2 °C). The concentration of free Ca2 and pH of all of our solu-
tions were determined using a Ca2 electrode and a pH elec-
trode (Hanna Instruments, Bedfordshire, UK) as previously
described (20). Our measurements showed that the addition of
Zn2 100 M had no significant effect on the concentration
of free Ca2 ([Ca2] was 10  3.8 M in the absence of Zn2
and 10 3.2 M in the presence of 100 M Zn2 (n 3). The
addition of 1 mM BAPTA reduced the free Ca2 concentration
from 10 2 M to 10 3.8 nM (n 3). Subsequent addition of
ZnCl2 (100M) had no significant effect on themeasured free
Ca2 concentration (10  3.2 nM; n  3) under these condi-
tions. The total concentration of Zn2 in all of our recording
solutionswas assessed using inductively coupled plasma optical
emission spectrometry (ICP-OES) (University of Edinburgh,
Grant Institute, commercial facility) and shown to be below the
detectable limit (1 ppb). Free Zn2 was also assessed using a
pZnmeter and calculated to be9 pM. The addition of concen-
trations of Ca2  100 M had no significant effect on the
concentration of free Zn2 ([Zn2] was 9  7 pM in the pres-
ence of 10MCa2 and 10 6 pMwhenCa2was raised to 100
M; n  3). The calculated free Zn2 concentration following
addition of 1mM cytosolic BAPTAwas first estimated using the
MaxChelator program and then assessed by actual measure-
ments of free Zn2 using a pZn meter. When the starting free
Ca2 concentration was 10 M, the addition of 1 mM BAPTA
had no significant effect on free Zn2 levels.
Single Channel Recording and Analysis—Single-channel cur-
rents were monitored under voltage-clamp conditions using a
BC-525C amplifier (Warner Instruments, Harvard Instru-
ments). Channel recordings were low pass filtered at 10 kHz
with a 4-pole Bessel filter, digitized at 100 kHz using a National
Instruments acquisition interface (NIDAQ-MX; National
Instruments, Austin, TX), and recorded on a computer hard
drive usingWinEDR 3.05 software (John Dempster, University
of Strathclyde, Glasgow, UK). The recordings were subse-
quently filtered at 800 Hz (3 dB) using a low pass digital filter
implemented in WinEDR 3.05. Channel events were detected
by the 50% threshold method (24) using TAC 4.2.0 software
(Bruxton Corporation, Seattle,WA). Open probability (Po) and
lifetime distributions were calculated from 3min of continuous
recording using TACfit 4.2.0 software (Bruxton Corporation).
Lifetime analysis was carried out only when a single channel
was incorporated into the bilayer. Individual lifetimes were fit-
ted to a probability density function using the method of max-
imum likelihood (24). Lifetimes of 	1 ms were not fully
resolved under the conditions of data acquisition described
here and were therefore excluded from the fitting procedure. A
missed events correction was applied as previously described
(25).
Ca2 Waves—Adult male Wistar rats (300–400 g) were
killed by concussion followed by cervical dislocation. The care
and sacrifice of the animals conformed to the requirements of
Directive 2010/63/EU of the European Parliament.
Isolation of Cardiomyocytes—All extracellular solutions were
based on a modified Tyrode’s solution. The basic solution con-
tained, 135 mM NaCl, 5 mM KCl, 330 M NaH2PO4, 5 mM glu-
cose, 5 mM sodium pyruvate, 10 mM HEPES, 1 mM MgCl2, and
2 mM CaCl2 (pH 7.4). Nominally Ca2-free Tyrode’s solution
used during cardiomyocyte isolationwas as outlined abovewith
no added Ca2.
The protocol for isolation of cardiomyocytes was as
described previously (26). Briefly, the whole heart was rapidly
excised and placed into cold, nominally Ca2-free Tyrode’s
solution (NT). The heart was then cannulated via the aorta on a
Langendorff type apparatus andwarmedNTbuffer at 37 °Cwas
perfused through the heart in a retrograde fashion for 6 min to
clear residual blood. The solution was then exchanged for a
Ca2-free NT buffer with enzyme mix (containing 15 mg of
collagenase type II (Worthington), with 50 mg of bovine serum
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albumin prepared from Cohn fraction V albumin and 18 mg of
protease (type XIV 15% Ca2) in 30 ml) for 8–15 min. Identi-
fication of rod-shaped cardiomyocytes in the perfusate was
used as an indication of digestion being complete. The solution
was then exchanged for a 2mMCa2NT solution, the heart was
cut down, and cardiomyocytes were mechanically dispersed
from the tissue in a shaking water bath. Typically this method
yielded 70–90% rod-shaped cardiomyocytes, which were
stored in NT solution at room temperature and used within
18 h of isolating. In intact myocytes, cells were exposed to
ZnCl2 in the presence of the zinc ionophore, zinc pyrithione
(ZnPy) to enable the entry of Zn2 into the cell because ZnCl2 is
cell-impermeable.
Cell Permeabilization—Isolated cardiomyocytes were permea-
bilized using saponin. Briefly, cardiomyocytes were perfused with
0.5mMCa2Tyrode’s solution for 2min prior to perfusionwith a
solutioncontaining100MEGTA,5mMATP, 10mMHEPES, 150
mMpotassiumgluconate, 25MMgCl2 at 20 °C.The sarcolemmal
membrane was permeabilized with saponin (50 g/ml) for 30 s.
After permeabilization, cardiomyocytes were maintained in
recording solution containing 1 mM EGTA, 10 mM HEPES, 120
mM potassium gluconate, 5 mM ATP, 1 mM pyruvate, 1 mM free
MgCl2, and 100 nM free Ca2 (calculated using the MaxChelator
program), and 30 M Fluo-4, pH 7.2. 1 mM BAPTA was added as
indicated in the text, andadditionalZn2wasaddedtomaintainas
required.
FIGURE 1. The effect of Zn2onRyR2gating.A, a typical single RyR2 channel showing the effect of sequential additions of Zn2 to the cis-chamber (cytosolic
face of the channel) in the presence of 10M activating Ca2with Ca2 as permeant ion at a holding potential of 0 mV. Open and closed states are shown by
O and C, respectively. B, the relationship between Zn2 concentration and RyR2 Po. Error bars show themean values S.E. (n 5; *, p	 0.05). C, the effects of
Zn2 on open and closed lifetime distributions of RyR2. Open (left) and closed (right) lifetime distributions and probability density functions of a typical RyR2
channel in the presence of 10M cytosolic Ca2 alone (control) and after sequential addition of 100 pM, 1 nM, 100 nM, and 100M Zn2 to the cytosolic face of
the channel. The best fits to the data were obtained by maximum likelihood fitting. Time constants and percentage areas are shown for each distribution.
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Imaging—Images from permeabilized cardiomyoyctes were
recorded using an Olympus 1X81 confocal microscope system
usingOlympus Fluoview software (version 4.0). Line scanswere
recorded using a 60 oil immersion lens using 2  2 pixel
binning where each pixel was 0.43m in diameter. Fluo-4 indi-
cator was excited using a 488-nm laser, and line scans were
acquired at a rate of 333 Hz. The data were analyzed offline
using ImageJ software. In our Tyrode’s solution alone, in the
presence of 100 nM Ca2, there was no significant change in
Fluo-4 fluorescence with increasing concentrations of Zn2
(
Fluo-4 F/F0 0.026 0.01 units in 10 nM Zn2 compared with
control Tyrode’s solution with no ZnCl2 added). For the car-
diomyocyte experiments, ZnCl2 stocks were made directly in
Tyrode’s solution because the maximum concentration of
Zn2 used was 100 nM. For measurements of Ca2 or Zn2 in
intact cardiomyocytes using Fluo-4-AMor Zinpyr-1, cells were
illuminated with 488 nm using a monochromator (Photon
Technology International, Birmingham, NJ) with fluorescence
emissions captured above 520 nm using a Cascade 512B CCD
camera (Photometrics, Tuscan, AZ) and continuously perfused
FIGURE 2.HCl buffer and TPENhave no effect on RyR2 gating. The top traces in A and B show representative single RyR2 channel current fluctuations using
10 M Ca2 as the sole activating ligand. The bilayer was voltage-clamped at 0 mV. The lower traces in A and B show that addition of the HCl buffer (A) or the
additionof 100nMTPEN (B) to the cis-chamberhadno significant effect on channelPo. Theopenandclosed channel levels aredenotedbyO andC, respectively.
The bar charts in A and B show both the average Po and the individual data points following the addition of the HCl buffer (A, n 6) or 100 nM TPEN (B, n 7).
The data are expressed as means S.E.
TABLE 1
Comparison of the changes in RyR2 channel gating in response to Zn2
The table shows the open and closed lifetime parameters in the presence of 10M cytosolic Ca2 and following the addition of Zn2 (100 pM to 100M) to the cytosolic face
of the channel. The values are means S.E. (n 3).
T1 T2 T3 T4
[Zn2] Time Area Time Area Time Area Time Area
ms % ms % ms % ms %
Open lifetime parameters
Control 1.0 0.05 89.0 3.0 5.0 0.9 11.0 3
100 pM 1.0 0.1 88.0 1.2 4.6 0.6 12.0 1.0 15.0 8.0 2.0 1.0
1 nM 1.0 0.1 62.9 9.0 4.5 0.78 32.0 8.0 27.0 4.0 4.6 2.5
100 nM 1.2 0.3 55.0 14.0 5.2 0.84 34.0 6.0 21.2 4.5 10.6 9.0
100 M 2.2 0.4 46.5 0.9 10.2 3.6 43.0 8.0 60.6 20 10.2 6.8
Closed lifetime parameters
Control 1.1 0.1 85.8 3.9 5.9 0.9 39.3 0.5 25.3 1.8 24.6 6.3 170.0 12.7 6.8 3.1
100 pM 1.0 0.1 72.0 2.3 5.3 0.6 26.0 2.6 46.0 15.0 2.3 0.3
1 nM 1.0 0.0 75.0 5.3 6.0 1.7 21.6 5.5 42.5 13.4 3.0 1.0 184.0 27.0 1.3 0.6
100 nM 1.1 0.1 48.0 19.8 4.7 1.2 36.5 3.7 31.1 1.3 15.0 18.0
100 M 1.0 0.1 62.3 11.1 6.4 2.4 30.3 6.5 41.7 17.2 7.3 5.1
Intracellular Zn2Modulates RyR2 Gating
17602 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 28•JULY 10, 2015
 at U
niv of St A
ndrew









at 32  2 °C. The data were acquired using EasyRatioPro soft-
ware (Photon Technology International, Birmingham, NJ) and
analyzed using Winfluor v3.6.8 software (John Dempster, Uni-
versity of Strathclyde, Glasgow, UK).
Contractile Measurements—Spontaneous contractions were
measured from cardiomyocytes perfused with Tyrode’s solu-
tion at 32 1 °C where videos were recorded to DVD. Analysis
of contractions was carried out using edge detection measure-
ments in Winfluor version 3.6.8 software.
Statistics—The data were expressed as means  S.E. Where
appropriate, a Student’s t test was used to assess the difference
betweenmean values. A p value of 0.05 was taken as significant.
Where multiple treatments were compared, ANOVA followed
by a Bonferroni post hoc test was used to assess the difference
between treatments. A p value of 0.05 was taken as significant.
Results
Effect of Zn2 on RyR2 Function—To determine whether
Zn2 can alter RyR2 gating, single RyR2 channels were incor-
porated into phospholipid bilayers enabling the membrane
environment to be carefully controlled, and the direct action of
Zn2 at the cytosolic face of the channel was studied. Using
Ca2 as a permeant ion and holding at a command potential of
0mV,which is considered to be the restingmembrane potential
of the sarcoplasmic reticulum (27), the addition of 100 pMZn2
to the cytosolic face of RyR2 channels significantly increased
FIGURE 3. The effect of Zn2 on RyR2 gating in the presence of a peak levels of Ca2. A, subsequent effect of Zn2 on RyR2 activation following exposure
of the channel to 100 M Ca2 with Ca2 as permeant ion, at a holding potential of 0 mV. O is the open state, and C is the closed state. B, the relationship
between RyR2 Po and the concentration of Zn
2 in the continued presence of 10 M Ca2 (open squares) or 100 M Ca2 (open circles) is shown. The average
Po using 10M (black dotted line) or 100M Ca
2 (gray dotted line) as the sole ligand is shown for comparison. Error bars show themean Po value S.E. (n 5).
C, open (left) andclosed (right) lifetimedistributions for the channel shown inA in thepresenceof 10Mcytosolic Ca2alone (control), after raising the cytosolic
Ca2 to a peak concentration of 100 M and following the sequential addition of 1 and 100 nM Zn2 to the cytosolic face of the channel in the continued
presence of 100 M Ca2. The best fits to the data were obtained by maximum likelihood fitting. Time constants and percentage areas are shown for each
distribution.
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channel Po from 0.10  0.03 to 0.45  0.04 (Fig. 1), indicating
that RyR2 has high affinity for Zn2. The potentiation of RyR2
gating by physiological concentrations of free Zn2 suggests
that the amount of Ca2 released through a single RyR2 chan-
nel following activation by cytosolic Ca2 is significantly
greater than previously thought. When Zn2 levels were incre-
mented in a cumulative fashion, channel activation plateaued at
1 nMZn2, and higher concentrations of Zn2 (10 nM) had no
further significant effect on channel Po (Fig. 1B). Physiological
concentrations of Zn2will therefore play a key role in regulat-
ing graded Ca2 release events via RyR2 channels, enabling
flexibility in the force of cardiac contraction, permitting the
heart to adjust to altered diastolic filling (28). The addition of 1
mM Zn2 to the cytosolic face of RyR2 completely abolished all
channel openings (Fig. 1, A and B), possibly a consequence of
Zn2 binding to the low affinity divalent inhibitory site of RyR2
(29). Control HCl buffer solution containing no Zn2 had no
significant effect on RyR2 gating (Fig. 2A). To confirm that the
level of free Zn2 in our recording solutions, which was mea-
sured at9 pM, was insufficient to influence channel gating, we
exposed RyR2 channels to the potent Zn2 chelator TPEN. In
the absence of exogenously added Zn2, the addition of 100 nM
TPEN to the cis-chamber caused no significant change in chan-
nel Po (Fig. 2B).
Mechanisms by Which Zn2 Regulates RyR2 Gating—To
investigate the mechanisms underlying RyR2 activation by
Zn2, we performed lifetime analysis on experiments where
only a single RyR2 channel was gating in the bilayer. Dwell time
histograms of the apparent open and apparent closed states
uncovered three modes of Zn2 operation at the cytosolic face
of RyR2 (Fig. 1C). Control channel-gating was best character-
ized by short openings and long closing as described previously
(30, 31). The addition of Zn2 in the concentration range 100
pM to 10 nM appeared to sensitize RyR2 to cytosolic Ca2,
revealed by a reduction in the duration of all the closed states
with little effect on the duration of channel openings (32).
When the free Zn2 concentration was elevated to 1 nM,
RyR2 dwelled for longer sojourns in the open state and dis-
played briefer sojourns in the closed state (see Table 1 for aver-
age lifetime data). This type of gating is characteristic of Ca2-
independent channel openings (21).
It is clear from the presented data that activating Zn2-bind-
ing sites exist on the cytosolic face of RyR2. To assess whether
Zn2 binds to the same cytosolic activation sites on RyR2 as
Ca2, we first exposed RyR2 to a concentration of cytosolic
Ca2 known to elevate Po to peak levels (100 M) (30) and then
added subsequent cumulative doses of Zn2 to the cytosolic
face of the channel (Fig. 3). In the presence of 100 M cytosolic
Ca2 and using Ca2 as permeant ion, subsequent addition of
cytosolic Zn2 in the range 1 nM to 100 M had no significant
effect on RyR2 Po. Lifetime analysis, however, showed that at
concentrations of Zn2 1 nM channel gating was altered, and
the channel dwelled in longer-lived open states, consistent with
Ca2-independent channel openings (21). These data suggest
that at least someof theZn2-binding sites are distinct from the
Ca2-binding sites. Irrespective of whether the concentration
of cytosolic Ca2 was 10 or 100 M, the addition of 1 mM cyto-
solic Zn2 was always found to abolish channel openings. This
suggests that in addition to high affinity Zn2 activation sites,
RyR2 also has low affinity Zn2 inhibition sites.
We next examined the interplay between Zn2 and Ca2 at
the cytoplasmic face of RyR2 (Fig. 4). Using Ca2 as permeant
ion and holding at a command potential of 0 mV, when the free
Ca2 was reduced to a subactivating concentration (	10 nM)
by the addition of 1 mM BAPTA, as expected, the Po value for
RyR2 reduced to zero (31). The subsequent addition of 1 nM
Zn2 to the cytosolic face of the channel had no effect on Po,
FIGURE 4. The effect of Zn2 on RyR2 gating at a subactivating concen-
tration of Ca2. The top trace in A shows a typical single RyR2 channel with
cytosolic Ca2 as the sole activating ligand and using Ca2 as the permeant
ion. The bilayer was voltage-clamped at 0 mV. Subsequent addition of 1 mM
BAPTA lowers the Ca2 concentration to	10 nM, which is subactivating, and
as expected the channel closes. Subsequent addition of 1 nM Zn2 to the
cytosolic face of the channel has no effect, and the channel remains closed.
Subsequent addition of 100 nM Zn2 to the cytosolic face of the channel
causes the channel to open. These openings are independent of Ca2. Fur-
ther elevation in the Zn2 concentration causes further channel activation.
The open and closed states are denoted by O and C, respectively. The mean
data in B show that there is a critical concentration of Zn2 (10 nM), above
which RyR2 openings are independent of the cytosolic Ca2 concentration
and channel openings are regulated solely by Zn2. The data show themean
values S.E. (n 5).
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and the channel remained closed because under these condi-
tions, channel gating is dependent on activation by cytosolic
Ca2. The subsequent addition of Zn2 in the range 100 nM to
100 M, however, resulted in channel activations. This is
important because RyR2 is now gating in a Ca2-independent
manner, whereby Zn2 is the sole activating ligand and the
need for Ca2 to activate the channel is removed.
Effects of Cytosolic Zn2 on Calcium Waves in Cardiac
Cells—We then measured the effect of Zn2 on Ca2 waves
recorded in isolated cardiomyocytes to provide evidence for the
modulation of RyR2 function byZn2 in a cellular environment
(Fig. 5). In these experiments, cardiomyocytes were permeabi-
lized to allow the intracellular concentration of Zn2 to be con-
trolled, and Ca2 fluorescencemeasurements weremade using
Fluo-4. In control recording conditions, where cardiomyocytes
were perfused with an intracellular solution containing 100 nM
free Ca2, there were no appreciable change in Ca2 release
from the intracellular stores. Perfusionwith increasing concen-
trations of Zn2 (between 100 pM and 10 nM Zn2), however,
caused a marked increase in both the incidence of spontaneous
Ca2 waves and the amplitude of these events in a Zn2
concentration-dependent manner (Fig. 5C). Increasing the
Zn2 concentration to 100 nM caused a marked decrease in
the amplitude and frequency of waves, and the cardiomyocytes
entered an irreversible series of Ca2 waves often culminating
in hypercontracture resulting in a loss of membrane integrity.
This concentration of Zn2 is close to the pathophysiological
concentration of Zn2 previously reported (30 nM) (33–36).
Interestingly, lowering the concentration of cytosolic Ca2 to
subactivating levels while maintaining the concentration of Zn2
did not diminish the Zn2-induced frequency of the Ca2 waves
seen in the permeabilized cells. In the presence of 100 nM Zn2,
removal of Ca2 by chelation with 1 mM BAPTA markedly
reduced the wave amplitude (Fig. 6), presumably as a result of
substantial Ca2 buffering. We next examined the caffeine-in-
duced release of SRCa2 in intact cardiomyocytes in the presence
FIGURE5.Theeffectof intracellularZn2onthe frequencyandamplitudeof spontaneousCa2waves in isolatedcardiomyocytes.A,panels iand ii show
a representative imageof Fluo-4 fluorescence in a cardiomyocyte in control and1nMZn2 solution.B, a confocal line scan recording taken froma5-pixel region
of interest of Fluo-4 fluorescence from a single cardiomyocyte in control (panel i), 0.1 nM Zn2 (panel ii), and 1 nM Zn2 (panel iii). Confocal line scan recorded
from the dotted line as indicated in A. C, the bar charts show themean number of Ca2waves (panel i) and themean amplitude of the waves from cardiomyo-
cytes with increasing concentrations of Zn2 (panel ii). (*, p	 0.05; ***, p	 0.001; one-way ANOVAwith Bonferroni’s post-hoc test, n 6 cardiomyocytes per
data set).
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and absence of the ZnPy in Tyrode’s solution containing 100 pM
Zn2 (Fig. 7).The increase inFluo-4 fluorescenceonapplicationof
5mM caffeine wasmarkedly potentiated by treatment with 10M
ZnPy, suggesting that the increase in intracellular Zn2 enhanced
the caffeine-induced Ca2 release via RyR2. Consistent with our
single channel studies, this shows that Zn2 can directly influence
cellular Ca2 dynamics through direct modulation of RyR2. The
finding that Zn2 can act as the sole activator of RyR2 highlights a
potential pathophysiological consequence of dysregulated Zn2
homeostasis. Such a deleterious cycling of intracellular Ca2with
pathophysiological concentrations of Zn2 could be arrhythmo-
genic in the intact myocardium.
Further evidence to suggest that changes in intracellular Zn2
levels have amarked effect on cellular cardiac contractions comes
from raising intracellular Zn2 levels by pretreating intact car-
diomyocytes with 10MZnPy and exposing these cells to 100 pM
extracellular ZnCl2. Under these conditions, there was a signifi-
cant increase in the inward current carried by Zn2 (Fig. 8,A and
B), and a concomitant increase in intracellular Zn2 measured
using the fluorescent indicator Zinpyr-1 (Fig. 8, C and D). As
shown by edge detection measurements, this resulted in sponta-
neous contractions compared with control cells (Fig. 9, A and B).
The observed spontaneous contractions were reversed by chelat-
ing intracellularZn2by theadditionof10MTPEN(Fig. 9,Cand
D), confirming that these cellular effects are attributed to elevated
intracellular Zn2 levels.
Discussion
In this study, we reveal that cytosolic Zn2 is a high affinity
activator of RyR2, effective at low picomolar concentrations.
FIGURE 6. The effect of buffering intracellular Ca2with BAPTA on wave amplitude and frequency in isolated cardiomyocytes. A, an example image of an
isolated cardiomyocyte in control (panel i), in 10 nMZn2 solution (panel ii), and in 10 nMZn2 solution containing 1mMBAPTA (panel iii). B, an example confocal line
scan and associated fluorescence changes froma5-pixel regionof interest in control (panel i), in 10 nMZn2 solution (panel ii), and in 10nMZn2 solution containing
1mMBAPTA (panel iii).C,bar charts compare themeannumberofCa2waves (panel i) and themeanwaveamplitude incontrol andafter treatmentwith1mMBAPTA
with increasing concentrations of Zn2 (panel ii) (***, p	 0.001; two-way ANOVAwith Bonferroni’s post-hoc test, n 6 cardiomyocytes per data set).
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Lifetime analysis of RyR2 reveals unique and distinctive gating
characteristics dependent on the concentration of cytosolic
Zn2. When Zn2 levels are in the range 100 pM to 1 nM, RyR2
activation occurs by sensitization of the channel to cytosolic
Ca2. When the concentration of Zn2 is elevated above 1 nM,
the effect of Zn2 overrides the influence of cytosolic Ca2, and
removal of activating levels of cytosolic Ca2 no longer influ-
ences channel Po. When Zn2 is elevated to toxic levels (in the
millimolar range), it inhibits RyR2 channel function. Further
evidence for the modulation of RyR2 function by Zn2 in iso-
latedpermeabilizedcardiomyocyteswasacquired throughmea-
surement of Ca2 waves. In these recordings, spontaneous
Ca2 waves were markedly increased in both frequency and
amplitude in a Zn2 concentration-dependent manner
(between 100 pM and 10 nM Zn2). Removal of Ca2 by chela-
tion with 1mM BAPTA did not abolish Ca2waves in the pres-
ence of Zn2, showing that Zn2 can directly influence Ca2
dynamics. These findings suggest an important pathophysio-
logical consequence of dysregulated Zn2 homeostasis,
whereby even a small increase in RyR2 open probability during
diastole can have major consequences for normal cardiac func-
tion and the generation of arrhythmias (37).
It is well established thatmicromolar concentrations of cyto-
solic Ca2 are required to activate RyR2 (38, 39). The potenti-
ation of RyR2 activity by physiological concentrations of Zn2
that we now show suggests that Zn2 plays a key role in shaping
intracellular Ca2 responses in cardiac muscle. Tight regula-
tion of intracellular Zn2will therefore be required for the con-
trolled release of Ca2 from SR stores because very small
changes in the concentration of free Zn2willmodify the open-
ing of RyR2 channels in response to very small rises in cytosolic
Ca2, and thismay cause channels to become leaky during dias-
tole. Under pathophysiological conditions, where Zn2 home-
ostasis is disturbed and levels of Zn2 may reach 1 nM, we
propose that Zn2 becomes themain activating ligand of RyR2.
Under these conditions, RyR2 starts to gate in exceptionally
long open states. The ability of 1 nM Zn2 to activate RyR2
reveals that Zn2 is a high affinity activator of RyR2 displaying
approximately 3 orders of magnitude higher affinity for RyR2
than Ca2. This alters the current model of cardiac excitation-
contraction coupling where it is accepted that a transient
changes in the concentration of intracellular Ca2 is the only
trigger for SR Ca2 release and reveals a new role for Zn2 in
shaping intracellular calcium responses in cardiac muscle.
Determination of the exact levels of intracellular Zn2 under
physiological and pathophysiology conditions is an ongoing
area of research, but the development of more sensitive Zn2
probes that are able tomeasure low concentrations of free Zn2
in single living cells is rapidly advancing (40). At reported
pathophysiological levels of cytosolic Zn2 (30 nM) (33–36),
we show that increases in RyR2 activity are the result of large
increases in the lifetime duration of the open channel state
rather than an increase in the frequency of openings and this is
characteristic of a Ca2-independent component of channel
gating. In the presence of 10 nM free Zn2, we show that
chelation of cytosolicCa2 is no longer able to closeRyR2 chan-
nels. This is because there is sufficient Zn2 present to directly
open the channel. The balance of intracellular Zn2 is therefore
crucial in switchingRyR2 channels froma “Ca2-dependent” to
a “Ca2-independent” mode of gating.
Ourmechanistic approach has for the first time revealed that
Zn2 is a potent activator of RyR2. Previous studies in which
cardiac muscle [3H]ryanodine binding assays were used to
assess the effects of Zn2 on RyR2 function failed to see any
effect of Zn2 between 10 nM and 1M in the presence of 50M
activating Ca2 (41). This is not surprising because our data
now reveal that in the presence of peak levels of Ca2, the effect
of Zn2 on channel Po is masked. Only by lifetime analysis of
our single channel data could we reveal that the mode of chan-
FIGURE 7. Elevated intracellular Zn2 levels increase the caffeine-in-
duced Ca2 release. A, example trace showing Fluo-4 fluorescence from
three cardiomyocytes perfused with 100 pM Zn2-Tyrode’s solution with
applications of 5 mM caffeine in the absence and presence of 10 M ZnPy. B,
mean change in Fluo-4 fluorescenceonapplicationof 5mMcaffeine in 100pM
Zn2-Tyrode’s control solution and after application of 10 M ZnPy (n  4
experiments (66 cardiomyocytes) from2animals; ***,p	 0.001, paired t test).
FIGURE 8. Elevated extracellular zinc levels result in an increase in the
concentration of intracellular zinc. A, example whole cell recording show-
ing the development of an inward current on application of a Tyrode’s solu-
tion containing an additional 100 pM Zn2 to an isolated cardiomyocyte volt-
age-clamped at 0 mV. B, mean data showing the increase in current from
basal in 100 pM Zn2 and washout (n 4 cardiomyocytes from 2 animals; **,
p	 0.01, repeated-measuredANOVAwith Bonferroni’s post-test).C, example
fluorescence recordings from three cardiomyocytes loaded with 10 M Zin-
pyr-1 showing that application of 10 M ZnPy facilitates an increase in intra-
cellular Zn2 when extracellular Zn2 is increased. D, mean change in intra-
cellular Zinpyr-1 fluorescence in control, in the presence of ZnPy and after
application of TPEN (n 4 experiments (156 cardiomyocytes) from2 animals;
***, p	 0.001; one-way ANOVA with Bonferroni’s post-test.).
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nel gating in the presence of Zn2 (1 nM) was altered and that
this type of gatingwas consistentwithCa2-independent open-
ings.Our single channel data also provide the first evidence that
when the concentration of Zn2 is elevated above 1 nM, RyR2
becomes directly activated by Zn2, and the dependence of
Ca2 on channel activation is abolished.
It is notable that previous studies have shown a slow accu-
mulation of intracellular Zn2 following prolonged exposure of
cardiomyocytes to micromolar levels of extracellular Zn2 and
that this results in a reduced SR Ca2 load (42). One plausible
explanation for these findings, based on our current data, is that
an elevation in intracellular Zn2 removes the Ca2 depen-
dence of RyR2 causing channels to gate in exceptionally long-
lived open states. Further evidence for this is demonstrated in
intact cardiomyocytes where, in a 100 pM Zn2-Tyrode’s solu-
tion, the caffeine-induced elevation in intracellular Ca2 was
potentiated only after application of 10 M ZnPy. Potentially
this will lead to inappropriate Ca2 release from the SR and
likely result in reduced SR Ca2 load. Such amechanismwould
be particularly problematic under conditions where levels of
intracellular Zn2 are chronically elevated, including diabetes
(36) and certain models of dystrophy (43). In line with previous
studies (41, 44), we also demonstrated an inhibitory action of
Zn2 on RyR2 gating when cytosolic Zn2 is raised to non-
physiological and toxicmillimolar concentrations. It is possible
that the inhibitory action of Zn2 on RyR2 may be a conse-
quence of Zn2 binding to the low affinity unspecific divalent
inhibitory site of RyR2 (29, 45).
Aberrant Zn2 homeostasis has been shown to be associated
with cardiomyopathy (46–48), but the underlying mechanism
of how Zn2 contributes to cardiac pathology is unknown.
Chronic oxidative stress is a major contributor in the patho-
physiology of heart failure and under these conditions intracel-
lular levels of Zn2 increase by as much as 30-fold (36). This
increase in Zn2 is primarily the result of altered metallothio-
nein function, which perturbs its binding of Zn2, resulting in
raised levels (49, 50). Also, recently, a polymorphism in a
human gene coding for amember of themetallothionein family
has been discovered, and individuals with diabetes who carry
this polymorphism have been shown to be more likely to
develop cardiovascular complications including chronic heart
failure and myocardial damage (51). Diabetic cardiomyopathy
is characterized by dysregulation of intracellular Ca2 release,
which consequently reduces cardiac contractility and signifi-
cantly prolongs the rise of systolicCa2 leading to chronic heart
failure (16). The controlled release of Ca2 from the SR during
FIGURE 9. Elevated intracellular Zn2 can evoke spontaneous contractions in intact cardiomyocytes. A, edge detection measurements from a single
cardiomyocyte treated with 10 M ZnPy in control (panel i), with an additional 10 pM ZnCl2 (panel ii), and with an additional 100 pM ZnCl2 showing increasing
spontaneous contractionswith increasing [Zn2] (panel iii). B, mean percentage of cardiomyocytes showing spontaneous contractionswith increasing [Zn2]
in the presence (black circles) and absence (white circles) of 10M ZnPy (n 4 experiments (100 cardiomyocytes) from 2 animals for each data set). C, mean
percentage of cardiomyocytes showing spontaneous contractions before (dashed line) and after (gray circles) pretreatment with 10M TPEN. Cardiomyocytes
were perfused either with control-Tyrode’s solution alone or with an additional 10 or 100 pM Zn2-Tyrode’s solution with 10M ZnPy. D, mean percentage of
cells showing spontaneous contractions in 100 pM Zn2 in the absence or presence of 10 M ZnPy and with 10 M ZnPy plus 10 M TPEN (n 4 experiments
(100 cardiomyocytes) from 2 animals for each data set; **, p	 0.01; one-way ANOVA with Bonferroni’s post-test).
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cardiac excitation-contraction coupling is known to govern
contractility of the heart. RyR2 plays a fundamental role as the
main pathway for the release of Ca2 and drives cellular con-
traction. Consequently dysfunction in the release of Ca2 and
modulatory influences that control RyR2 function are identi-
fied as contributory to the pathophysiology of heart failure and
fatal cardiac arrhythmias (1). The presented study therefore
provides a mechanistic explanation as to how raised levels of
intracellular Zn2 may contribute to the progression of con-
tractile dysfunction and heart failure through the alteration of
RyR2 gating, which will result in perturbed Ca2 release.
A simple model to explain how cytosolic Zn2 modulates
RyR2 gating is shown in Fig. 10. We suggest that under physio-
logical conditions, cytosolic Zn2 is able to fine-tune the release
of Ca2 from the SR while in parallel enabling flexibility and
control of SR Ca2 dynamics mediated through RyR2. Under
pathophysiological conditions, where Zn2 homeostasis is dis-
turbed and levels of Zn2may reach1 nM, RyR2 starts to gate
in exceptionally long open states, which leads to very high Po
potentially leading to arrhythmia. In this conformation, RyR2 is
uncoupled from the usual regulatory effects of cytosolic Ca2
and RyR2 channels are now activated by solely by Zn2.
Our study reveals that RyR2-mediated Ca2 homeostasis is
intimately related to intracellular Zn2 levels and provides a
mechanistic explanation as to how altered Zn2 homeostasis
can modulate cardiac RyR2 function. We reveal that Zn2 is a
high affinity activator of RyR2 which challenges our under-
standing of cardiac excitation-contraction coupling. We sug-
gest that under normal physiological conditions, intracellular
Zn2 is essential in fine-tuning the release of Ca2 from the SR.
Pathological perturbations in Zn2 homoeostasis will lead to
inappropriate release of Ca2 as observed in certain cardiac
abnormalities including heart failure and fatal arrhythmias.
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